Latest Conference Articles

Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

Final APPLY-PNH Data Support Use of Iptacopan in PNH With Persistent Anemia

Oral iptacopan (Fabhalta) monotherapy induced durable responses and hemolysis control in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia who had previously received anti-C5 treatment.

Brentuximab Vedotin Combo Elicits Responses in Advanced Classical Hodgkin Lymphoma

Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine was found to have efficacy and acceptable safety and tolerability when used as a frontline treatment in patients with previously untreated advanced, classical Hodgkin lymphoma.

Acalabrutinib With or Without Obinutuzumab Provides Sustained PFS Benefit in Previously Untreated CLL

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.

Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS

Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

Odronextamab produced durable responses and a generally manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

MRD-Guided Ibrutinib Plus Venetoclax Improves Survival in Treatment-Naive CLL

Ibrutinib plus venetoclax, given at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia.

Retrospective Analysis Supports Utilization of Auto-HCT in Relapsed LBCL Achieving a CR

Autologous hematopoietic cell transplantation lowered relapse and progression rates and improved survival outcomes vs CAR T-cell therapy in patients with relapsed large B-cell lymphoma who experienced complete remission with interim treatment.

Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden

Obecabtagene autoleucel elicited durable responses in patients with relapsed or refractory B-cell acute lymphoblastic leukemia independent of leukemic burden at lymphodepletion, although better outcomes were observed in those with lower burden.

Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.

MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML

The presence of molecular minimal residual disease following induction chemotherapy can be used to determine patients with NPM1-mutated acute myeloid leukemia who may benefit from allogeneic transplant in first remission, including those with FLT3 ITD–mutated disease.

Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome

The high-precision cell therapy Orca-T demonstrated high rates of relapse-free survival, overall survival, and graft-vs-host disease RFS at 1 year, as well as a low incidence of GVHD in patients with intermediate- to high-risk myelodysplastic syndrome.

Orca-T Demonstrates Feasibility in Older Patients With Hematologic Malignancies

The use of Orca-T with myeloablative chemotherapy conditioning had comparable safety and efficacy in younger and older patients with hematologic malignancies, according to data from a phase 1b study.

Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL

The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.

Venetoclax Is Associated With Durable ORRs in Real-World Population of BTK Inhibitor–Exposed CLL/SLL

Venetoclax-based therapy generated durable responses both overall and in the second or third line following covalent BTK inhibitor discontinuation in real-world patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Ultrasensitive BCMA CARs Deliver Responses With Tolerable Safety in R/R Multiple Myeloma

The use of the BCMA-directed CAR T-cell therapy D8 Fab CAR and the dual-targeting AUTO8 CAR T-cell therapy is safe and feasible in patients with relapsed/refractory multiple myeloma.

Golidocitinib Demonstrates Efficacy in Relapsed/Refractory PTCL

Golidocitinib displayed antitumor activity and an acceptable safety profile in patients with refractory/relapsed peripheral T-cell lymphoma, according to data from the pivotal phase 2 JACKPOT8 study.

Pirtobrutinib Demonstrates Durable Efficacy in Covalent BTK Inhibitor–Pretreated CLL/SLL

Pirtobrutinib continued to showcase clinically meaningful efficacy in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a covalent BTK inhibitor.

Safety of Outpatient CAR T-Cell Therapy May Be Improved With Integrated Management Process

The utilization of remote patient monitoring within the first 30 days of outpatient CAR T-cell therapy can promote patient safety, reduce costs, and decrease hospitalization rates by allowing patients with hematologic malignancies to connect with a virtual care platform.

Zanubrutinib Showcases Sustained PFS Benefit Vs Ibrutinib in R/R CLL/SLL

Zanubrutinib continued to demonstrate improved progression-free survival benefit over ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, according to extended follow-up data from the phase 3 ALPINE trial.

Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL

Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.

Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL

Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.

Brexu-Cel Induces Responses in Real-World Population of High-Risk R/R MCL

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.